Mereo BioPharma Group PLC (LON:MPH) Insider Denise Scots-Knight Buys 13,500 Shares

Mereo BioPharma Group PLC (LON:MPH) insider Denise Scots-Knight acquired 13,500 shares of the company’s stock in a transaction dated Thursday, September 19th. The shares were purchased at an average cost of GBX 59 ($0.77) per share, with a total value of £7,965 ($10,407.68).

Denise Scots-Knight also recently made the following trade(s):

  • On Thursday, August 15th, Denise Scots-Knight acquired 6,000 shares of Mereo BioPharma Group stock. The shares were purchased at an average cost of GBX 54 ($0.71) per share, with a total value of £3,240 ($4,233.63).
  • On Thursday, July 18th, Denise Scots-Knight acquired 10,000 shares of Mereo BioPharma Group stock. The shares were purchased at an average cost of GBX 51 ($0.67) per share, with a total value of £5,100 ($6,664.05).

Shares of LON MPH traded up GBX 1 ($0.01) during mid-day trading on Friday, hitting GBX 60.50 ($0.79). 2,721 shares of the stock were exchanged, compared to its average volume of 266. The company has a market cap of $59.27 million and a P/E ratio of -1.34. The stock’s fifty day simple moving average is GBX 50.76 and its two-hundred day simple moving average is GBX 98.99. The company has a debt-to-equity ratio of 65.56, a quick ratio of 2.05 and a current ratio of 2.13. Mereo BioPharma Group PLC has a twelve month low of GBX 40 ($0.52) and a twelve month high of GBX 268 ($3.50).

Mereo BioPharma Group Company Profile

Mereo BioPharma Group plc, a specialty biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of rare and specialty diseases. Its product candidates include BPS-804, a monoclonal antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfecta; AZD-9668, an oral small molecule that has been completed Phase I clinical trial to treat Alpha-1 antitrypsin deficiency; BGS-649, an oral aromatase inhibitor, which is in Phase IIb clinical trial for the treatment of hypogonadal hypogonadism; and BCT-197, an oral p38 MAP kinase inhibitor that is in Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease.

Featured Story: How is a management fee different from a performance fee?

Receive News & Ratings for Mereo BioPharma Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mereo BioPharma Group and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit